Table 1
| Disease Site |
Study | Study Name | Open Date | Number of Active Institutions |
Number of Current IRBs |
|---|---|---|---|---|---|
| BREAST | S1418 | Breast, Adj, TNBC, MK-3475 (Pembrolizumab) | 15-NOV-16 | 415 | 209 |
| S1706 | Breast, Inflammatory, RT +/- Olaparib | 12-SEP-18 | 201 | 100 | |
| S2007 | Breast, Brain Mets, Sacituzumab Govitecan | 15-DEC-20 | 48 | 25 | |
| A011202 | Breast, Nodal XRT +/- ALND | 07-FEB-14 | 310 | 170 | |
| A011401 | Breast, adj, Stage II/III HER2-, weight loss | 29-AUG-16 | 0 | 225 | |
| A011801 | BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib | 06-JAN-21 | 14 | 11 | |
| EA1131 | Brst, TNBC, Post-op Chemo vs Obs | 20-AUG-14 | 276 | 129 | |
| EA1181 | BRST, HER2-pCR, Preop THP and Postop HP | 11-FEB-20 | 192 | 110 | |
| EA1183 | Brst, Met, FDG PET Assess Response, FEATURE | 02-APR-20 | 7 | 6 | |
| MA39 | BREAST, Node-Pos, Reg RT vs No Reg RT | 30-MAY-18 | 253 | 112 | |
| NRGBR003 | Brst,Adj,TNBC,AC -> WP +/- Carbo | 22-JAN-15 | 310 | 153 | |
| NRGBR004 | BREAST, Met HER2+, Pac+Tras+Pert +/- Atezo | 12-MAR-19 | 362 | 160 | |
| CCD | S1703 | Met Breast, STM-monitoring v Usual Care | 16-JUL-18 | 206 | 82 |
| A231601C | CCD, OPTI-Surg in older cancer patients | 01-APR-19 | 102 | 34 | |
| EA1151 | CCD, Tomosynthesis Mammographic Screening | 06-JUL-17 | 183 | 88 | |
| EAQ171CD | Smoke Free Support Study 2.0 | 11-APR-19 | 5 | 31 | |
| NHLBIMDS | LEUK, National MDS Study | 05-APR-16 | 209 | 97 | |
| NRGCC007 | CCD, Increased Dose of SCP in Pros Survivors | 27-MAR-19 | 9 | 5 | |
| ERLYTX | S1609 | Rare Tumor, Comb Nivo/Ipi | 13-JAN-17 | 348 | 155 |
| EAY131 | MATCH | 12-AUG-15 | 368 | 198 | |
| GI | S1613 | mCRC, Adv/Met, TP vs CETIRI | 09-OCT-17 | 292 | 115 |
| S1922 | Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect | 16-DEC-19 | 148 | 54 | |
| S2001 | Rando II, Mets Pancreas , BRCA1/2, Comb Chemo | 04-DEC-20 | 72 | 36 | |
| A021502 | Colon, Stg III, Chemo +/- Atezol, ATOMIC | 12-SEP-17 | 354 | 179 | |
| A021602 | PANC, Adv PNET Blinded Cabozantinib v Placebo | 18-JUL-18 | 241 | 96 | |
| A021703 | COLON, Adv/Met, Chemo + Std v High dose V-D3 | 30-SEP-19 | 268 | 144 | |
| A021806 | Pancreas, Perioperative vs Adjuvant Chemo | 01-JUL-20 | 206 | 104 | |
| EA2142 | GI NEC, Adv G3, EP vs TMZ + CAP | 06-NOV-15 | 169 | 89 | |
| EA2165 | Anal, Stg II-III, Nivolumab after CMT | 13-APR-18 | 274 | 138 | |
| EA2186 | PANC, mets, Gem+Abraxane vs 5-FU+LV+Nal-IRI | 18-JUN-20 | 19 | 18 | |
| EA2187 | ICC, Carboplatin+Paclitaxel +/- Pevonedistat | 31-JAN-20 | 25 | 9 | |
| GU | S1802 | Pros, Stg IV, SST +/- Surg/RT to Primary Tum | 17-SEP-18 | 286 | 132 |
| S1806 | Blad, MIBC, ChemoRT +/- Atezolizumab | 19-APR-19 | 283 | 130 | |
| S1931 | RENAL, Stg IV, IO + Nephrectomy. vs IO Only | 16-NOV-20 | 59 | 34 | |
| S1937 | Blad, Mets, Eribulin +/- Gem vs SOC | 16-FEB-21 | 15 | 13 | |
| A031102 | GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) | 01-JUL-15 | 62 | 46 | |
| A031501 | Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs | 21-SEP-17 | 274 | 151 | |
| A031701 | Bladder, ddGC for MIBC with DDR Tumor Alt | 01-AUG-18 | 141 | 59 | |
| A031702 | GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) | 12-APR-19 | 205 | 96 | |
| A031704 | RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo | 09-MAY-19 | 229 | 116 | |
| A031801 | GU, mRCC, Cabozantinib +/- Radium-223 | 13-DEC-19 | 8 | 4 | |
| EA8143 | RCC, HR, Surg +/- Nivolumab (PROSPER) | 02-FEB-17 | 290 | 164 | |
| EA8153 | Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2) | 08-FEB-18 | 209 | 94 | |
| EA8171 | PROS, newly diagnosed, mpMRI for pre-op stagi | 09-JUL-18 | 93 | 43 | |
| NRGGU002 | Pros, RT + ADT After RP +/- Adj Docetaxel | 30-DEC-16 | 185 | 96 | |
| NRGGU005 | PROS, intmd risk, IGRT& SBRT vs IGRT& HF-IMRT | 16-NOV-17 | 278 | 125 | |
| NRGGU008 | Pros,Node+, Abiraterone acetate + Apalutamide | 05-MAR-20 | 158 | 70 | |
| LEUK | S1712 | CML, Chronic Phase, TKI +/- Ruxolitinib | 20-JUL-18 | 156 | 68 |
| S1905 | T-ALL/T-LBL, Rel/Ref, OBI-3424 | 17-AUG-20 | 41 | 22 | |
| S1925 | CLL/SLL, Newly Dx HR, Early vs Delayed V+O | 14-DEC-20 | 154 | 54 | |
| A041501 | B-Cell ALL, Frontline Tx +/- Intuzumab Ozo | 01-JUN-17 | 189 | 84 | |
| A041701 | AML, Age 60+, Conv Chemo +/- Uproleselan | 16-JAN-19 | 132 | 63 | |
| A041702 | CLL, Stg I-IV, IO with IM versus IVO | 04-JAN-19 | 268 | 121 | |
| A041703 | ALL, Dx, Inotuzumab Ozogamicin + Blinatumomab | 16-NOV-18 | 86 | 48 | |
| EA9161 | CLL, untreated, IOV vs IO in younger pts | 03-JAN-19 | 260 | 129 | |
| EA9171 | CML, Anti-PD-1 Pembrolizumab + TKIs | 03-OCT-18 | 85 | 38 | |
| EA9181 | ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab | 14-OCT-20 | 8 | 7 | |
| LUNG | S1701 | Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac | 09-AUG-18 | 109 | 41 |
| S1827 | SCLC, MRI Surveillance +/- PCI | 10-JAN-20 | 250 | 107 | |
| S1900B | RET Fusion: Selpercatinib (LOXO-292) | 10-FEB-20 | 257 | 122 | |
| S1900E | KRAS G12C: AMG 510 | 02-APR-21 | 59 | 27 | |
| S1914 | NSCLC, High Risk Early Stg, SBRT +/- Atezo | 25-MAR-20 | 236 | 89 | |
| S1929 | ESCLC, SLFN11+, Atezolizumab ± Talazoparib | 15-JUN-20 | 160 | 74 | |
| S1933 | NSCLC, Stg II-III, RT + Atezo | 15-JUN-20 | 97 | 47 | |
| A081801 | ALCHEMIST4, ALK and EGFR negative, Chemo-IO | 03-JUN-20 | 334 | 169 | |
| A151216 | ALCHEMIST0 - screening | 06-FEB-14 | 391 | 241 | |
| E4512 | ALCHEMIST2, ALK mut, Crizotinib | 18-AUG-14 | 378 | 214 | |
| EA5163 | NSCLC, Immunotherapy +/- 2nd line therapy | 28-FEB-19 | 302 | 131 | |
| EA5181 | NSCLC, Unresect Stg 3, Chemo/RT+/-MED4736 | 09-APR-20 | 232 | 91 | |
| EA5191 | NSCLC, Cabozantinib +/- Nivolumab vs Chemo | 22-MAY-20 | 162 | 64 | |
| LUNGMAP | NSCLC, Adv, Master | 28-JAN-19 | 356 | 182 | |
| NRGCC003 | SCLC, PCI or HA-PCI | 07-DEC-15 | 214 | 118 | |
| NRGLU002 | LUNG, Limited Met NSCLC, MST vs LCT + MST | 07-APR-17 | 261 | 126 | |
| NRGLU005 | LUNG, LS-SCLC, ChemoRT v ChemoRT+Atezo | 28-MAY-19 | 338 | 147 | |
| LYMPH | S1608 | FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob | 10-AUG-17 | 205 | 83 |
| S1826 | HD, Adv, Age 12+, N+AVD vs BV+AVD | 19-JUL-19 | 291 | 142 | |
| S1918 | DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP | 19-MAR-21 | 4 | 1 | |
| A051301 | ABC DLBCL, Auto HCT and Ibrutinib/Placebo | 06-JUL-16 | 156 | 66 | |
| E4412 | HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin | 24-JAN-14 | 143 | 66 | |
| EA4151 | Lymph, AHCT +/-Ritux, MRD Neg | 29-AUG-17 | 148 | 74 | |
| EA4181 | MCL, Randomization BR/CR v BR/CR-A v BR-A | 03-OCT-19 | 170 | 72 | |
| MELAN | S1512 | Melan, Adv, Desmoplastic, MK-3475 (pembro) | 20-OCT-16 | 92 | 40 |
| S1801 | Melan, Adv, Adj vs Neoadj Pembrolizumab | 06-DEC-18 | 287 | 128 | |
| S2000 | MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo | 23-SEP-20 | 88 | 42 | |
| EA6134 | Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T | 15-DEC-15 | 275 | 119 | |
| EA6141 | Melan, Avd, Nivolumab+Ipi ± Sargmostim | 01-MAR-16 | 173 | 77 | |
| EA6174 | Merkel, Adjuvant Pembrolizumab vs Observation | 23-JUL-18 | 192 | 93 | |
| MMYEL | S1803 | MM, Maintenance, Len vs Len/Dara | 27-JUN-19 | 260 | 99 |
| EAA173 | MYEL, SMM, Rd +/- Daratumumab | 30-APR-19 | 208 | 82 | |
| OTHER | A091802 | cSCC, Advanced Avelumab +/- Cetuximab | 17-MAY-19 | 123 | 60 |
| A091902 | Sarcoma, Paclit +/- Nivo and Nivo + Caboz | 04-SEP-20 | 23 | 12 | |
| A151804 | irAEs, National Biorepository to Adv Studies | 31-JAN-20 | 150 | 71 | |
| ARST1431 | Sarcoma, IR RMS, Randomized VAC/VI +/- TORI | 23-MAY-16 | 116 | 84 | |
| EA3132 | HN SCC, Stg III-IV , Adj RT +/- Cisp | 29-MAR-16 | 192 | 70 | |
| EA3161 | HNC, HPV+ OPCA, (cisplatin+RT) +/- Nivo | 20-JUN-19 | 200 | 85 | |
| EA3163 | Nasal, T3 vs T4a, Surgery+RT +/- NeoAdj CT | 28-MAR-18 | 81 | 40 | |
| EAF151 | Brain, GBM, Bev, Blood Volume | 14-APR-17 | 70 | 26 | |
| G0263 | Cerv, Stg I/IIA, adjv RT vs chemoRT | 12-APR-10 | 151 | 62 | |
| N0577 | BRN, Glio,Tem vs Tem+RT vsRT+PVC | 22-SEP-09 | 212 | 82 | |
| NCICOVID | NCI COVID-19 in Cancer Patients Study | 21-MAY-20 | 316 | 170 | |
| NRGBN001 | HN, novel vs. std chemoradiation + chemo | 28-AUG-15 | 145 | 71 | |
| NRGBN003 | Mening, Grd II, Observation vs Irradiation | 14-JUN-17 | 234 | 96 | |
| NRGGY005 | OVAR, Cedir vs Olaparib vs C+O vs Std of Care | 06-FEB-16 | 303 | 131 | |
| NRGHN001 | Nasopharyngeal , Indiviual Tx EBV | 21-APR-14 | 157 | 76 | |
| NRGHN004 | HN, Adv, RT+Durvalumab vs RT+Cetuximab | 12-DEC-17 | 282 | 122 | |
| NRGHN005 | HN, early stg P16-pos, randomize de-intensifi | 10-JUL-19 | 286 | 117 | |
| R0724 | Cervical, Chem+RT +/- Adj. Chemo | 15-JAN-14 | 0 | 78 | |
| R1216 | HN, Adv,Cis vs Dtx vs Dtx+Cetux | 18-MAR-13 | 246 | 99 | |
| PEOLC | S1820 | Rectal, Diet modification to manage GI sx | 09-DEC-19 | 198 | 73 |
| PREV | S1823 | GCT, Obs. Cohort, miRNA371 | 01-JUN-20 | 102 | 53 |
| S1904 | Breast, Decision making for chemoprevention | 01-SEP-20 | 17 | 39 | |
| A211601 | Breast, Stg II-III, Aspirin | 01-AUG-18 | 134 | 61 | |
| EA2185 | Impact of Panc Cyst Surveillance | 16-JAN-20 | 4 | 3 | |
| SURV | S1501 | Surv, Breast Stg IV, Card Tox w/ Carvedilol | 15-SEP-17 | 234 | 98 |
| E1Q11 | EROS: Reproductive Health in Cancer Survivors | 30-SEP-15 | 0 | 44 | |
| SXQOL | S1600 | Bladder,Radical Cystectomy Outcomes Nutrition | 21-FEB-19 | 132 | 39 |
| S1714 | CIPN Risk Prediction Cohort Study, Taxanes | 01-MAR-19 | 145 | 63 | |
| A221505 | Brst, Hypofractionated Post Mast Rad | 01-FEB-18 | 234 | 109 | |
| A221602 | CINV in HEC patients, Olanza +/- Fosapre | 15-OCT-18 | 116 | 74 | |
| A221702 | BREAST, SLN/ALND +/- ARM | 31-MAY-19 | 207 | 75 | |
| A221805 | Colorectal, Duloxetine for Oxaliplatin CIPN | 01-MAY-20 | 10 | 13 | |
| EAZ171 | Breast, Stg I-III, TIPN Docetaxel/Paclitaxel | 27-JUN-19 | 108 | 59 | |